Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6198 participants.
Also called NCT01101035
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,198 participants
- Sponsor
- Registry
-
NCT01101035 -
U1111-1114-4194
-
- Other papers using this trial's data
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
- Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities
- Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Mexico
- Registry status
- Completed
Technical summary
Registry record NCT01101035. Randomized; quadruple masking; primary purpose treatment. Start 2010-04-23 (actual); primary completion 2017-05-15 (actual). Results posted on 2018-06-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
- Acronym
- CARES
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- Febuxostat
- Intervention (Drug)
- Allopurinol
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01101035- Content hash
aea5c25aa80c1db2fd8fdefba36d5e3d48fa69758cd812fab8f966c3da0ae7e8